Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause
NCT06206408 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Fezolinetant in Japanese Women Experiencing Vasomotor Symptoms (Hot Flashes) Associated With Menopause
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 16, 2024
- Completion date
- December 18, 2025
- Enrollment
- 410 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.